Treating Hepatitis C in CRF Using Sofosbuvir and Daclatasvir

PHASE4CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

April 1, 2017

Primary Completion Date

September 1, 2018

Study Completion Date

February 1, 2019

Conditions
Hepatitis C, ChronicChronic Renal Failure
Interventions
DRUG

Sofosbuvir 400 mg and daclatasvir 60 mg

Daily fixed dose combination pill (Sovodak) containing 400 mg sofosbuvir and 60 mg daclatasvir for 12 weeks if not cirrhotic (liver stiffness \< 12 KPa) or 24 weeks if cirrhotic

Trial Locations (1)

14117

Shariati Hospital, Tehran

All Listed Sponsors
collaborator

Ahvaz Jundishapur University of Medical Sciences

OTHER

collaborator

Shiraz University of Medical Sciences

OTHER

collaborator

Hamadan University of Medical Science

OTHER

lead

Tehran University of Medical Sciences

OTHER

NCT03063879 - Treating Hepatitis C in CRF Using Sofosbuvir and Daclatasvir | Biotech Hunter | Biotech Hunter